Circulating levels of DDIT4 and mTOR, and contributions of BMI, inflammation and insulin sensitivity in hyperlipidemia

Pan,Xinyan; Zhang,Zhimei; Liu,Chunqiao; Zhao,Ming; Wang,Xing; Zhai,Junqing; Wang,Chao; Song,Guangyao

doi:10.3892/etm.2022.11602

Circulating levels of DDIT4 and mTOR, and contributions of BMI, inflammation and insulin sensitivity in hyperlipidemia

Authors:
- Xinyan Pan
- Zhimei Zhang
- Chunqiao Liu
- Ming Zhao
- Xing Wang
- Junqing Zhai
- Chao Wang
- Guangyao Song
View Affiliations

Affiliations: Department of Internal Medicine, Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China, Clinical Laboratory, Hebei General Hospital, Shijiazhuang, Hebei 050051, P.R. China, Hebei Key Laboratory of Metabolic Diseases, Hebei General Hospital, Shijiazhuang, Hebei 050051, P.R. China, Hebei Provincial Physical Examination Center, Hebei General Hospital, Shijiazhuang, Hebei 050051, P.R. China
Published online on: September 8, 2022 https://doi.org/10.3892/etm.2022.11602
Article Number: 666
Copyright: © Pan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Evidence shows a high incidence of insulin resistance, inflammation and excess body mass index (BMI) in adults with hyperlipidemia. The present study aimed to determine the circulating levels of DNA damage inducible transcript 4 (DDIT4) and mTOR and assess the contributions of lipids, inflammatory markers, insulin sensitivity and BMI in hyperlipidemia. The study subjects were divided into a hyperlipidemia group and a normal control group (n=55 per group). Sex, age, blood pressure, waist circumference (WC), height, weight and BMI were recorded. Fasting venous blood samples were collected and an automatic biochemical analyzer was used to detect fasting blood glucose (FBG), fasting insulin (FINS), total cholesterol (TC), triglyceride (TG), high‑density lipoprotein cholesterol (HDL‑C) and low‑density lipoprotein cholesterol (LDL‑C). Quantitative ELISA kits were used to determine the levels of DDIT4, mTOR and inflammatory markers and calculate the homeostatic model assessment of insulin resistance (HOMA‑IR). Compared with the normal control group, the hyperlipidemia group had significantly increased blood pressure, WC, weight, BMI, FBG, FINS, HOMA‑IR, mTOR and inflammatory markers, but significantly reduced DDIT4. A concurrent correlation analysis showed that insulin resistance was positively correlated with blood pressure, BMI, lipid profiles (TG, TC, LDL‑C), mTOR and inflammatory markers, but negatively correlated with HDL‑C and DDIT4. Lipid profiles were positively correlated with BMI, mTOR and inflammatory markers, but negatively correlated with DDIT4. A factor analysis identified four domains in hyperlipidemia (inflammation‑lipid 1 domain, 44.429%; overweight domain, 21.695%; insulin sensitivity domain, 11.782%; lipid 2 domain, 6.723%). In conclusion, people with hyperlipidemia have elevated mTOR and reduced DDIT4 and are accompanied by abnormal indicators such as insulin sensitivity, BMI and inflammatory factors. The identified domains may be applied to predict the outcomes of cardiovascular diseases and metabolic diseases in the future.

View Figures

View References

1	Tomlinson B, Chan P and Lam CW: Postprandial hyperlipidemia as a risk factor in patients with type 2 diabetes. Expert Rev Endocrinol Metab. 15:147–157. 2020.PubMed/NCBI View Article : Google Scholar
2	Zhu JR, Gao RL and Zhao SP: Guidelines for the prevention and treatment of dyslipidemia in Chinese adults (Revised edition 2016). Chinese Circulation Journal. 31:937–953. 2016.(in Chinese).
3	Wang L, Lu MY, Ren JY and Chen H: Correlation study on different dyslipidemia classification and glucose metabolism in patients with hyperlipidemia. Beijing Da Xue Xue Bao Yi Xue Ban. 43:427–431. 2011.PubMed/NCBI(In Chinese).
4	Koundouros N and Blenis J: Targeting mTOR in the context of diet and whole-body metabolism. Endocrinology. 163(bqac041)2022.PubMed/NCBI View Article : Google Scholar
5	Dennis MD, Coleman CS, Berg A, Jefferson LS and Kimball SR: REDD1 enhances protein phosphatase 2A-mediated dephosphorylation of Akt to repress mTORC1 signaling. Sci Signal. 7(ra68)2014.PubMed/NCBI View Article : Google Scholar
6	Ellisen LW, Ramsayer KD, Johannessen CM, Yang A, Beppu H, Minda K, Oliner JD, McKeon F and Haber DA: REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species. Mol Cell. 10:995–1005. 2002.PubMed/NCBI View Article : Google Scholar
7	Kimball SR, Do AN, Kutzler L, Cavener DR and Jefferson LS: Jefferson LS rapid turnover of the mTOR complex 1 (mTORC1) repressor REDD1 and activation of mTORC1 signaling following inhibition of protein synthesis. Biol Chem. 283:3465–3475. 2008.PubMed/NCBI View Article : Google Scholar
8	Katiyar S, Liu E, Knutzen CA, Lang ES, Lombardo CR, Sankar S, Toth JI, Petroski MD, Ronai Z and Chiang GG: REDD1, an inhibitor of mTOR signalling, is regulated by the CUL4A-DDB1 ubiquitin ligase. EMBO Rep. 10:866–872. 2009.PubMed/NCBI View Article : Google Scholar
9	Papapanagiotou A, Siasos G, Kassi E, Gargalionis AN and Papavassiliou AG: Novel inflammatory markers in hyperlipidemia: Clinical implications. Curr Med Chem. 22:2727–2743. 2015.PubMed/NCBI View Article : Google Scholar
10	Siasos G, Tousoulis D, Oikonomou E, Zaromitidou M, Stefanadis C and Papavassiliou AG: Inflammatory markers in hyperlipidemia: From experimental models to clinical practice. Curr Pharm Des. 17:4132–4146. 2011.PubMed/NCBI View Article : Google Scholar
11	Butani L, Dharmar M, Devaraj S and Jialal I: Preliminary report of inflammatory markers, oxidative stress, and insulin resistance in adolescents of different ethnicities. Metab Syndr Relat Disord. 14:182–186. 2016.PubMed/NCBI View Article : Google Scholar
12	Tarantino G, Citro V, Balsano C and Capone D: Could SCGF-beta levels be associated with inflammation markers and insulin resistance in male patients suffering from obesity-related NAFLD? Diagnostics (Basel). 10(395)2020.PubMed/NCBI View Article : Google Scholar
13	Chinese Adult Dyslipidemia Prevention and Treatment Guidelines Revision Joint Committee: Guidelines for the prevention and treatment of dyslipidemia in Chinese adults (Revised edition 2016). Chinese Journal of General Practitioners 16: 15-35, 2017 (in Chinese).
14	Sun J, Du Q and Wang GP: Research on β cell function and insulin resistance in patients with type 2 diabetes mellitus. Chin J Diabetes. 23:592–594. 2015.
15	Xiao-Yan X, Wen-Ying Y and Zhao-Jun Y: The diagnostic significance of homeostasis model assessment of insulin resistance in metabolic syndrome among subjects with different glucose tolerance. Chinese J Diabetes Mellitus. 2004:31–35. 2004.
16	Yuan H and Yuan F: Study on the relationship between pure hyperlipidemia and insulin resistance index. Chinese Journal of Practical Internal Medicine. 27:246–247. 2007.(in Chinese).
17	Qiu LQ: Comparison of clinical effects of two statins in the treatment of primary hyperlipidemia. Guide of China Medicine. 9:85–86. 2011.(in Chinese).
18	Wang XG and Zhao X: Research progress of pathogenesis and treatment of hyperlipidemia. Journal of Liaoning University of Traditional Chinese Medicine. 22:196–200. 2020.(in Chinese).
19	Schmelzle T and Hall MN: TOR, a central controller of cell growth. Cell. 103:253–262. 2000.PubMed/NCBI View Article : Google Scholar
20	Sudarsanam S and Johnson DE: Functional consequences of mTOR inhibition. Curr Opin Drug Discov Devel. 13:31–40. 2010.PubMed/NCBI
21	Laplante M and Sabatini DM: mTOR signaling in growth control and disease. Cell. 149:274–293. 2012.PubMed/NCBI View Article : Google Scholar
22	Carlson CJ, White MF and Rondinone CM: Mammalian target of rapamycin regulates IRS-1 serine 307 phosphorylation. Biochem Biophys Res Commun. 316:533–539. 2004.PubMed/NCBI View Article : Google Scholar
23	Sarbassov DD, Ali SM and Sabatini DM: Growing roles for the mTOR pathway. Curr Opin Cell Biol. 17:596–603. 2005.PubMed/NCBI View Article : Google Scholar
24	Ozes ON, Akca H, Mayo LD, Gustin JA, Maehama T, Dixon JE and Donner DB: A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1. Proc Natl Acad Sci USA. 98:4640–4645. 2001.PubMed/NCBI View Article : Google Scholar
25	Ting H, Zhen-Zhen L, Yang B and Hui-Shuang L: Probiotics improve lipid metabolism of obese mice induced by high-fat and high-sucrose diet. Basic Clin Med. 41:1260–1265. 2021.
26	Ding L and Liu YC: Study on improving nonalcoholic fatty liver disease of high fat diet induced rats by corn silk aqueous extract. China Food Additives. 32:51–57. 2021.(in Chinese).
27	Gordon BS, Williamson DL, Lang CH, Jefferson LS and Kimball SR: Nutrient-induced stimulation of protein synthesis in mouse skeletal muscle is limited by the mTORC1 repressor REDD1. J Nutr. 145:708–713. 2015.PubMed/NCBI View Article : Google Scholar
28	Dungan CM and Williamson DL: Regulation of skeletal muscle insulin-stimulated signaling through the MEK-REDD1-mTOR axis. Biochem Biophys Res Commun. 482:1067–1072. 2017.PubMed/NCBI View Article : Google Scholar
29	Dungan CM, Wright DC and Williamson DL: Lack of REDD1 reduces whole body glucose and insulin tolerance, and impairs skeletal muscle insulin signaling. Biochem Biophys Res Commun. 453:778–783. 2014.PubMed/NCBI View Article : Google Scholar
30	Regazzetti C, Dumas K, Marchand-Brustel YL, Peraldi P, Tanti JF and Giorgetti-Peraldi S: Regulated in development and DNA damage responses -1 (REDD1) protein contributes to insulin signaling pathway in adipocytes. PLoS One. 7(e52154)2012.PubMed/NCBI View Article : Google Scholar
31	Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL and Sabatini DM: Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell. 22:159–168. 2006.PubMed/NCBI View Article : Google Scholar
32	Wang H, Wang JM, Qu H, Wei H, Ji B, Yang Z, Wu J, He Q, Luo Y, Liu D, et al: In vitro and in vivo inhibition of mTOR by 1,25-dihydroxyvitamin D3 to improve early diabetic nephropathy via the DDIT4/TSC2/mTOR pathway. Endocrine. 54:348–359. 2016.PubMed/NCBI View Article : Google Scholar
33	Yang Z, Liu F, Qu H, Wang H, Xiao X and Deng H: 1,25(OH)₂D3 protects cell against high glucose-induced apoptosis through mTOR suppressing. Mol Cell Endocrinol. 414:111–119. 2015.PubMed/NCBI View Article : Google Scholar
34	Liang D, Zhao SQ, Li ZY, Xiao YW, Ding J, Xiao Y and Guo B: miR-22 promotes DNA damage of renal tubular epithelial cells with diabetic kidney disease by inhibiting DDIT4. Chin J Pathophysiol. 37:1933–1941. 2021.(In Chinese).
35	Xu MC, Shi HM, Wang H and Gao XF: Salidroside protects against hydrogen peroxide-induced injury in HUVECs via the regulation of REDD1 and mTOR activation. Mol Med Rep. 8:147–153. 2013.PubMed/NCBI View Article : Google Scholar
36	Jin HO, Seo SK, Woo SH, Kim ES, Lee HC, Yoo DH, An S, Choe TB, Lee SJ, Hong SI, et al: Activating transcription factor 4 and CCAAT/enhancer-binding protein-beta negatively regulate the mammalian target of rapamycin via Redd1 expression in response to oxidative and endoplasmic reticulum stress. Free Radic Biol Med. 46:1158–1167. 2009.PubMed/NCBI View Article : Google Scholar
37	Whitney ML, Jefferson LS and Kimball SR: ATF4 is necessary and sufficient for ER stress-induced upregulation of REDD1 expression. Biochem Biophys Res Commun. 379:451–455. 2009.PubMed/NCBI View Article : Google Scholar
38	Chen DP, Ma YP, Zhuo L, Zhang Z, Zou GM, Yang Y, Gao HM and Li WG: 1,25-Dihydroxyvitamin D3 inhibits the proliferation of rat mesangial cells induced by high glucose via DDIT4. Oncotarget. 9:418–427. 2018.PubMed/NCBI View Article : Google Scholar
39	Chen H, Chen Y, Wu W, Chen Z, Cai Z, Ch Z, Yan X and Wu S: Prolonged hyperlipidemia exposure increases the risk of arterial stiffness in young adults: A cross-sectional study in a cohort of Chinese. BMC Public Health. 20:1091–1099. 2020.PubMed/NCBI View Article : Google Scholar
40	Miao J, Zang X, Cui X and Zhang J: Autophagy, hyperlipidemia, and atherosclerosis. Adv Exp Med Biol. 1207:237–264. 2020.PubMed/NCBI View Article : Google Scholar
41	López-Mejías R, Genre F, Remuzgo-Martínez S, González-Juanatey C, Robustillo-Villarino M, Llorca J, Corrales A, Vicente E, Miranda-Filloy JA, Magro C, et al: Influence of elevated-CRP level-related polymorphisms in non-rheumatic Caucasians on the risk of subclinical atherosclerosis and cardiovascular disease in rheumatoid arthritis. Sci Rep. 6(31979)2016.PubMed/NCBI View Article : Google Scholar
42	Chang CJ, Jian DY, Lin MW, Zhao JZ, Ho LT and Juan CC: Evidence in obese children: contribution of hyperlipidemia, obesity-inflammation, and insulin sensitivity. PLoS One. 10(e0125935)2015.PubMed/NCBI View Article : Google Scholar
43	Lin MW, Hwu CM, Huang YH, Sheu WH, Shih KC, Chiang FT, Olshen R, Chen YD, Curb JD, Rodriguez B, et al: Directly measured insulin resistance and the assessment of clustered cardiovascular risks in hypertension. Am J Hypertens. 19:1118–1124. 2006.PubMed/NCBI View Article : Google Scholar
44	Ding D, Li X, Qiu J, Li R, Zhang Y, Su D, Li Z, Wang M, Lv X and Wang D: , et al: Serum lipids, apolipoproteins, and mortality among coronary artery disease patients. Biomed Res Int. 2014(709756)2014.PubMed/NCBI View Article : Google Scholar
45	Wang X, Bao W, Liu J, Ouyang YY, Wang D, Rong S, Xiao X, Shan ZL, Zhang Y, Yao P and Liu LG: Inflammatory markers and risk of type 2 diabetes: A systematic review and meta-analysis. Diabetes Care. 36:166–175. 2013.PubMed/NCBI View Article : Google Scholar